线粒体DNA拷贝数与心血管疾病的关联
将mtDNA-CN加入2013年ACC/AHA汇总队列方程可改善10年动脉粥样硬化性CVD风险分类,并可能优化他汀起始治疗决策。
要点
- mtDNA-CN降低与冠心病、卒中及复合CVD风险独立相关。
- 将mtDNA-CN加入传统风险方程可改善风险分类。
- mtDNA-CN可能辅助指导他汀一级预防的启动。
核心结论
- 在三个大型前瞻性研究中,mtDNA-CN与 incident CVD 独立相关,可能具有改善CVD风险分类的潜在临床效用。
主要发现
- mtDNA-CN每降低1个标准差, incident 冠心病、卒中和CVD的风险比分别为1.29(95% CI 1.24-1.33)、1.11(95% CI 1.06-1.16)和1.23(95% CI 1.19-1.26)。
- 上述关联在调整传统CVD危险因素后持续存在。
- 将mtDNA-CN加入2013年ACC/AHA汇总队列方程后,风险分类改善(连续净重分类指数0.194;95% CI 0.130-0.258;P < .001)。
- mtDNA-CN进一步改善了2013年ACC/AHA关于启动他汀一级预防ASCVD建议的敏感性和特异性(净221人适当降级,净15人适当升级)。
临床怎么用
- mtDNA-CN或可作为额外生物标志物,辅助传统风险评分进行CVD风险分层。
- 在考虑他汀一级预防时,mtDNA-CN可能帮助识别更适合启动治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mitochondrial dysfunction is a core component of the aging process and may play a key role in atherosclerotic cardiovascular disease. Mitochondrial DNA copy number (mtDNA-CN), which represents the number of mitochondria per cell and number of mitochondrial genomes per mitochondrion, is an indirect biomarker of mitochondrial function. OBJECTIVE: To determine whether mtDNA-CN, measured in an easily accessible tissue (buffy coat/circulating leukocytes), can improve risk classification for cardiovascular disease (CVD) and help guide initiation of statin therapy for primary prevention of CVD. DESIGN, SETTING, AND PARTICIPANTS: Prospective, population-based cohort analysis including 21 870 participants (20 163 free from CVD at baseline) from 3 studies: Cardiovascular Health Study (CHS), Atherosclerosis Risk in Communities Study (ARIC), and Multiethnic Study of Atherosclerosis (MESA). The mean follow-up was 13.5 years. The study included 11 153 participants from ARIC, 4830 from CHS, and 5887 from MESA. Analysis of the data was conducted from March 10, 2014, to January 29, 2017. EXPOSURES: Mitochondrial DNA-CN measured from buffy coat/circulating leukocytes. MAIN OUTCOMES AND MEASURES: Incident CVD, which combines coronary heart disease, defined as the first incident myocardial infarction or death owing to coronary heart disease, and stroke, defined as the first nonfatal stroke or death owing to stroke. RESULTS: Of the 21 870 participants, the mean age was 62.4 years (ARIC, 57.9 years; MESA, 62.4 years; and CHS, 72.5 years), and 54.7% of participants were women. The hazard ratios for incident coronary heart disease, stroke, and CVD associated with a 1-SD decrease in mtDNA-CN were 1.29 (95% CI, 1.24-1.33), 1.11 (95% CI, 1.06-1.16), and 1.23 (95% CI, 1.19-1.26). The associations persisted after adjustment for traditional CVD risk factors. Addition of mtDNA-CN to the 2013 American College of Cardiology/American Heart Association Pooled Cohorts Equations for estimating 10-year hard atherosclerosis CVD risk was associated with improved risk classification (continuous net reclassification index, 0.194; 95% CI, 0.130-0.258; P < .001). Mitochondrial DNA-CN further improved sensitivity and specificity for the 2013 American College of Cardiology/American Heart Association recommendations on initiating statin therapy for primary prevention of ASCVD (net 221 individuals appropriately downclassified and net 15 individuals appropriately upclassified). CONCLUSIONS AND RELEVANCE: Mitochondrial DNA-CN was independently associated with incident CVD in 3 large prospective studies and may have potential clinical utility in improving CVD risk classification.
引用
- Ashar FN, Zhang Y, Longchamps RJ, et al. Association of Mitochondrial DNA Copy Number With Cardiovascular Disease. JAMA Cardiol. 2017. PMID: 29049454. doi:10.1001/jamacardio.2017.3683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。